Cetuximab Plus Methotrexate in Recurrent and/or Metastatic Head-and-Neck Squamous Cell Carcinoma
Background: The effectiveness of cetuximab (CTX) combined with methotrexate (MTX) has not yet been evaluated in patients with recurrent and/or metastatic head-and-neck squamous cell carcinoma (RM-HNSCC). Materials and Methods: A retrospective analysis of patients with RM-HNSCC who received 50 mg MTX...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-07-01
|
| Series: | Journal of Cancer Research and Practice |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103ejcrp.eJCRP-D-23-00010 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591007163613184 |
|---|---|
| author | Wen-Chen Tang Pei-Wei Huang Chien-Yu Lin Chia-Hsun Hsieh Cheng-Lung Hsu Shiang-Fu Huang Chun-Ta Liao Chih-Hua Yeh Nai-Ming Cheng Hung-Ming Wang* |
| author_facet | Wen-Chen Tang Pei-Wei Huang Chien-Yu Lin Chia-Hsun Hsieh Cheng-Lung Hsu Shiang-Fu Huang Chun-Ta Liao Chih-Hua Yeh Nai-Ming Cheng Hung-Ming Wang* |
| author_sort | Wen-Chen Tang |
| collection | DOAJ |
| description | Background:
The effectiveness of cetuximab (CTX) combined with methotrexate (MTX) has not yet been evaluated in patients with recurrent and/or metastatic head-and-neck squamous cell carcinoma (RM-HNSCC).
Materials and Methods:
A retrospective analysis of patients with RM-HNSCC who received 50 mg MTX weekly plus a standard dose of CTX for a maximum of 18 weeks, without maintenance CTX.
Results:
A total of 164 patients were included (cisplatin-sensitive, 88; cisplatin-refractory, 76). Among 58 cisplatin-sensitive patients receiving CTX/MTX as the first-line treatment, the outcomes were 39.7% response rate (RR), 70.7% disease control rate (DCR), 6.0 months of median progression-free survival (PFS), and 9.0 months of overall survival (OS). Among cisplatin-refractory patients, results were 31.6% RR, 51.3% DCR, 4.0 months of PFS, and 6.0 months of OS. Multivariable analyses revealed PFS and OS were not associated with cisplatin-refractory status, age, performance status, or the lines of CTX/MTX treatments. In cisplatin-refractory patients, those with only locoregional-recurrence disease had significantly worse PFS, but this did not affect OS; a similar trend was observed in cisplatin-sensitive patients.
Conclusion:
A CTX/MTX regimen, without maintenance CTX, is a safe and effective palliative treatment for both patients with cisplatin-sensitive or cisplatin-refractory RM-HNSCC. The low adverse events and easy administration makes this treatment a suitable option in various contexts, particularly for cisplatin-unfit or frail patients with RM-HNSCC. |
| format | Article |
| id | doaj-art-08db03dc24b14b69a0831cc475e15834 |
| institution | Kabale University |
| issn | 2311-3006 |
| language | English |
| publishDate | 2023-07-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Cancer Research and Practice |
| spelling | doaj-art-08db03dc24b14b69a0831cc475e158342025-01-23T05:07:04ZengWolters Kluwer Medknow PublicationsJournal of Cancer Research and Practice2311-30062023-07-0110310110910.4103ejcrp.eJCRP-D-23-00010Cetuximab Plus Methotrexate in Recurrent and/or Metastatic Head-and-Neck Squamous Cell CarcinomaWen-Chen TangPei-Wei HuangChien-Yu LinChia-Hsun HsiehCheng-Lung HsuShiang-Fu HuangChun-Ta LiaoChih-Hua YehNai-Ming ChengHung-Ming Wang*Background: The effectiveness of cetuximab (CTX) combined with methotrexate (MTX) has not yet been evaluated in patients with recurrent and/or metastatic head-and-neck squamous cell carcinoma (RM-HNSCC). Materials and Methods: A retrospective analysis of patients with RM-HNSCC who received 50 mg MTX weekly plus a standard dose of CTX for a maximum of 18 weeks, without maintenance CTX. Results: A total of 164 patients were included (cisplatin-sensitive, 88; cisplatin-refractory, 76). Among 58 cisplatin-sensitive patients receiving CTX/MTX as the first-line treatment, the outcomes were 39.7% response rate (RR), 70.7% disease control rate (DCR), 6.0 months of median progression-free survival (PFS), and 9.0 months of overall survival (OS). Among cisplatin-refractory patients, results were 31.6% RR, 51.3% DCR, 4.0 months of PFS, and 6.0 months of OS. Multivariable analyses revealed PFS and OS were not associated with cisplatin-refractory status, age, performance status, or the lines of CTX/MTX treatments. In cisplatin-refractory patients, those with only locoregional-recurrence disease had significantly worse PFS, but this did not affect OS; a similar trend was observed in cisplatin-sensitive patients. Conclusion: A CTX/MTX regimen, without maintenance CTX, is a safe and effective palliative treatment for both patients with cisplatin-sensitive or cisplatin-refractory RM-HNSCC. The low adverse events and easy administration makes this treatment a suitable option in various contexts, particularly for cisplatin-unfit or frail patients with RM-HNSCC.https://journals.lww.com/10.4103ejcrp.eJCRP-D-23-00010cetuximabhead-and-neck squamous cell carcinomametastaticmethotrexatepalliative treatmentrecurrence |
| spellingShingle | Wen-Chen Tang Pei-Wei Huang Chien-Yu Lin Chia-Hsun Hsieh Cheng-Lung Hsu Shiang-Fu Huang Chun-Ta Liao Chih-Hua Yeh Nai-Ming Cheng Hung-Ming Wang* Cetuximab Plus Methotrexate in Recurrent and/or Metastatic Head-and-Neck Squamous Cell Carcinoma Journal of Cancer Research and Practice cetuximab head-and-neck squamous cell carcinoma metastatic methotrexate palliative treatment recurrence |
| title | Cetuximab Plus Methotrexate in Recurrent and/or Metastatic Head-and-Neck Squamous Cell Carcinoma |
| title_full | Cetuximab Plus Methotrexate in Recurrent and/or Metastatic Head-and-Neck Squamous Cell Carcinoma |
| title_fullStr | Cetuximab Plus Methotrexate in Recurrent and/or Metastatic Head-and-Neck Squamous Cell Carcinoma |
| title_full_unstemmed | Cetuximab Plus Methotrexate in Recurrent and/or Metastatic Head-and-Neck Squamous Cell Carcinoma |
| title_short | Cetuximab Plus Methotrexate in Recurrent and/or Metastatic Head-and-Neck Squamous Cell Carcinoma |
| title_sort | cetuximab plus methotrexate in recurrent and or metastatic head and neck squamous cell carcinoma |
| topic | cetuximab head-and-neck squamous cell carcinoma metastatic methotrexate palliative treatment recurrence |
| url | https://journals.lww.com/10.4103ejcrp.eJCRP-D-23-00010 |
| work_keys_str_mv | AT wenchentang cetuximabplusmethotrexateinrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT peiweihuang cetuximabplusmethotrexateinrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT chienyulin cetuximabplusmethotrexateinrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT chiahsunhsieh cetuximabplusmethotrexateinrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT chenglunghsu cetuximabplusmethotrexateinrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT shiangfuhuang cetuximabplusmethotrexateinrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT chuntaliao cetuximabplusmethotrexateinrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT chihhuayeh cetuximabplusmethotrexateinrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT naimingcheng cetuximabplusmethotrexateinrecurrentandormetastaticheadandnecksquamouscellcarcinoma AT hungmingwang cetuximabplusmethotrexateinrecurrentandormetastaticheadandnecksquamouscellcarcinoma |